Safety Outcomes
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Safety Of DAPAGLIFLOZIN (FORXIGA) in Patient With Type 2 Diabetes Mellitus (T2dm) In Vietnam From A Post-Marketing Surveillance Program (NCT07210307) | AstraZeneca | 2017-10-31 |
Track Safety Outcomes automatically
Every clearance here is in the API, with alerts when new ones post.